These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 38778732)

  • 1. Clinical pharmacokinetics and pharmacodynamics of venetoclax, a selective B-cell lymphoma-2 inhibitor.
    Salem AH; Menon RM
    Clin Transl Sci; 2024 May; 17(5):e13807. PubMed ID: 38778732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Subjects with Hepatic Impairment.
    Salem AH; Dave N; Marbury T; Hu B; Miles D; Agarwal SK; Bueno OF; Menon RM
    Clin Pharmacokinet; 2019 Aug; 58(8):1091-1100. PubMed ID: 30949874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma.
    Agarwal SK; Salem AH; Danilov AV; Hu B; Puvvada S; Gutierrez M; Chien D; Lewis LD; Wong SL
    Br J Clin Pharmacol; 2017 Apr; 83(4):846-854. PubMed ID: 27859472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma.
    Salem AH; Agarwal SK; Dunbar M; Enschede SL; Humerickhouse RA; Wong SL
    J Clin Pharmacol; 2017 Apr; 57(4):484-492. PubMed ID: 27558232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics.
    Freise KJ; Hu B; Salem AH
    Eur J Clin Pharmacol; 2018 Apr; 74(4):413-421. PubMed ID: 29302721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Low- and High-Fat Meals on the Pharmacokinetics of Venetoclax, a Selective First-in-Class BCL-2 Inhibitor.
    Salem AH; Agarwal SK; Dunbar M; Nuthalapati S; Chien D; Freise KJ; Wong SL
    J Clin Pharmacol; 2016 Nov; 56(11):1355-1361. PubMed ID: 27029823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Azithromycin on Venetoclax Pharmacokinetics in Healthy Volunteers: Implications for Dosing Venetoclax with P-gp Inhibitors.
    Agarwal SK; Tong B; Bueno OF; Menon RM; Salem AH
    Adv Ther; 2018 Nov; 35(11):2015-2023. PubMed ID: 30264382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Predictors of Venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma Patients: a Pooled Population Pharmacokinetic Analysis.
    Jones AK; Freise KJ; Agarwal SK; Humerickhouse RA; Wong SL; Salem AH
    AAPS J; 2016 Sep; 18(5):1192-1202. PubMed ID: 27233802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Rifampin's Transporter Inhibitory and CYP3A Inductive Effects on the Pharmacokinetics of Venetoclax, a BCL-2 Inhibitor: Results of a Single- and Multiple-Dose Study.
    Agarwal SK; Hu B; Chien D; Wong SL; Salem AH
    J Clin Pharmacol; 2016 Nov; 56(11):1335-1343. PubMed ID: 26953185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model.
    Freise KJ; Shebley M; Salem AH
    J Clin Pharmacol; 2017 Jun; 57(6):796-804. PubMed ID: 28052338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exposure-Response Analyses of the Effects of Venetoclax, a Selective BCL-2 Inhibitor, on B-Lymphocyte and Total Lymphocyte Counts in Women with Systemic Lupus Erythematosus.
    Nader A; Minocha M; Othman AA
    Clin Pharmacokinet; 2020 Mar; 59(3):335-347. PubMed ID: 31541431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies.
    King AC; Peterson TJ; Horvat TZ; Rodriguez M; Tang LA
    Ann Pharmacother; 2017 May; 51(5):410-416. PubMed ID: 28056525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical evaluation of P-glycoprotein inhibition by venetoclax: a drug interaction study with digoxin.
    Chiney MS; Menon RM; Bueno OF; Tong B; Salem AH
    Xenobiotica; 2018 Sep; 48(9):904-910. PubMed ID: 29027832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Izutsu K; Yamamoto K; Kato K; Ishikawa T; Fukuhara N; Terui Y; Choi I; Humphrey K; Kim SY; Okubo S; Ogawa N; Nishimura Y; Salem AH; Maruyama D
    Int J Hematol; 2021 Mar; 113(3):370-380. PubMed ID: 33094474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of the B-Cell Lymphoma 2 (Bcl-2) Inhibitor Venetoclax in Female Subjects with Systemic Lupus Erythematosus.
    Minocha M; Zeng J; Medema JK; Othman AA
    Clin Pharmacokinet; 2018 Sep; 57(9):1185-1198. PubMed ID: 29333561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolism and Disposition of a Novel B-Cell Lymphoma-2 Inhibitor Venetoclax in Humans and Characterization of Its Unusual Metabolites.
    Liu H; Michmerhuizen MJ; Lao Y; Wan K; Salem AH; Sawicki J; Serby M; Vaidyanathan S; Wong SL; Agarwal S; Dunbar M; Sydor J; de Morais SM; Lee AJ
    Drug Metab Dispos; 2017 Mar; 45(3):294-305. PubMed ID: 27993930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Multiple Concomitant CYP3A Inhibitors on Venetoclax Pharmacokinetics: A PBPK and Population PK-Informed Analysis.
    Mukherjee D; Brackman DJ; Suleiman AA; Zha J; Menon RM; Salem AH
    J Clin Pharmacol; 2023 Jan; 63(1):119-125. PubMed ID: 35996877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bayesian Population Model of the Pharmacokinetics of Venetoclax in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from the Phase III MURANO Study.
    Deng R; Gibiansky L; Lu T; Agarwal P; Ding H; Li X; Kshirsagar S; Lu D; Li C; Girish S; Wang J; Boyer M; Humphrey K; Freise KJ; Salem AH; Seymour JF; Kater AP; Miles D
    Clin Pharmacokinet; 2019 Dec; 58(12):1621-1634. PubMed ID: 31209657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Venetoclax does not prolong the QT interval in patients with hematological malignancies: an exposure-response analysis.
    Freise KJ; Dunbar M; Jones AK; Hoffman D; Enschede SL; Wong S; Salem AH
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):847-53. PubMed ID: 27586967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancing venetoclax activity in hematological malignancies.
    Satta T; Grant S
    Expert Opin Investig Drugs; 2020 Jul; 29(7):697-708. PubMed ID: 32600066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.